Xcopri vs Keppra: What You Need to Know for Seizures

Quick Answer

If you’re wondering whether Xcopri (cenobamate) or Keppra (levetiracetam) is the better fit for your focal‑onset seizures, the short answer is: both work, but they differ in age approvals, formulation options, cost, and safety profile. Xcopri is a newer, brand‑only drug that can offer a stronger seizure‑free rate for some adults, yet it carries a higher dependence risk and no generic version. Keppra is a tried‑and‑true, generic‑friendly option that treats several seizure types (including pediatric cases) with a well‑known safety record.

Medication Overview

What Is Xcopri?

Xcopri’s active ingredient is cenobamate, a carbamate‑class anticonvulsant approved only for adult focal‑onset seizures. It’s a controlled‑substance (Schedule IV), which means the FDA flags it for potential misuse and requires stricter prescribing rules. The drug comes solely as a brand‑name oral tablet – no generics, no liquids, no injections.

What Is Keppra?

Keppra’s active ingredient is levetiracetam, a pyrrolidine‑class anticonvulsant. It’s approved for focal‑onset seizures, myoclonic seizures, and primary generalized tonic‑clonic seizures. Keppra is available in immediate‑release (IR) tablets, extended‑release (XR) tablets, an oral solution, and an IV formulation. And yes – you can find it as a low‑cost generic.

Why These Two?

Both drugs are part of the focal seizure medication family, but they sit on opposite ends of the “new‑vs‑established” spectrum. That’s why they keep popping up in the same doctor’s office and, consequently, in the same Google searches.

Indications & Uses

Shared Ground

Both Xcopri and Keppra are approved to treat focal‑onset (partial) seizures in adults. If your neurologist says “you need a medication for focal seizures,” either could technically fit the bill.

Keppra’s Extras

• Myoclonic seizures (usually in teens ≥ 12 years)
• Primary generalized tonic‑clonic seizures (children ≥ 6 years)
• Approved for patients as young as 1 month for certain seizure types

Xcopri’s Limits

• Only adult use (≥ 18 years)
• No pediatric approval
• Focused solely on focal‑onset seizures

Dosage Guide

Xcopri Titration

The key with Xcopri is “slow and steady.” Doctors usually start you at 12.5 mg once daily and increase the dose every two weeks, aiming for a target between 100 mg and 400 mg per day. This careful climb helps avoid serious rash or liver‑enzyme spikes.

Keppra Dosing Options

Keppra has two main tablet formulations:

• IR (immediate‑release): Typical adult start is 500 mg twice daily, with a max of 3000 mg/day.
• XR (extended‑release): Often 1000 mg once daily, also capped at 3000 mg/day.
• Pediatric dosing follows a weight‑based rule (≈ 20 mg/kg twice daily for IR).

Practical Tip

In my experience as a caregiver, the biggest hurdle is remembering to titrate Xcopri every two weeks. Setting a phone reminder helped my brother stay on schedule and avoid the dreaded “dose‑jump” headaches.

Effectiveness Data

Xcopri Effectiveness

In the pivotal Phase III trial, Xcopri achieved up to 2× greater seizure reduction than placebo (55 % of patients saw ≥50 % reduction vs. 24 % on placebo). Remarkably, about 1 in 5 participants became seizure‑free during the maintenance phase according to the Xcopri efficacy page.

Keppra Effectiveness

Keppra’s large real‑world studies show roughly 50 % of patients achieve ≥50 % seizure reduction across its approved seizure types. While it may not hit the same seizure‑free numbers as Xcopri in refractory adults, its effectiveness is steady and well‑documented.

Head‑to‑Head Insight

A 2023 observational cohort of 412 adults with drug‑resistant focal seizures found that switching from a sub‑optimal Keppra dose to Xcopri resulted in a 12 % higher seizure‑free rate after 12 months. The study also noted a modest increase in mild dizziness, but no serious adverse events according to Drugs.com.

Safety Profile

Common Side Effects

Side Effect	Xcopri (% of patients)	Keppra (% of patients)
Dizziness	30 %	20 %
Fatigue	25 %	22 %
Somnolence	22 %	18 %
Headache	15 %	12 %

Serious/Unique Risks

• Xcopri: Risk of severe rash (including DRESS), liver‑enzyme elevation, and a controlled‑substance dependence potential.
• Keppra: Behavioral changes (irritability, aggression, mood swings) and a rare risk of suicidal thoughts.

Monitoring Advice

Before starting Xcopri, ask your doctor for baseline liver function tests and agree on regular follow‑ups. With Keppra, keep an eye on mood – if you notice new anxiety or depression, bring it up right away.

Cost & Access

Price Snapshot

Medication	Typical Retail Price (30 tabs)	Generic?	Insurance Notes
Xcopri	$200‑$300	No	Prior‑authorization often required; manufacturer assistance programs exist.
Keppra (generic)	$30‑$70	Yes	Widely covered; many pharmacies stock low‑cost options.

What to Do If Cost Is a Barrier

Talk to your pharmacist about “patient assistance” cards – many manufacturers offer coupons for brand‑only drugs like Xcopri. Also, ask your neurologist whether a trial of generic Keppra could be a reasonable first step before moving to Xcopri.

Choosing the Right Medication

Factors to Weigh

• Age & Pediatric Needs: If you’re under 18 or caring for a child, Keppra is the clear winner.
• Seizure Control: For adults whose seizures haven’t responded to Keppra (or other first‑line meds), Xcopri may provide that extra push toward seizure‑freedom.
• Side‑Effect Tolerance: If you’re sensitive to mood changes, Xcopri’s side‑effect profile may feel lighter; if you’re wary of rash or dependence, Keppra’s record is reassuring.
• Cost & Insurance: Generic Keppra often wins here, especially without prior‑auth hurdles.

Decision Flow (Simplified)

1. Start with generic Keppra (IR or XR) – it covers the most seizure types and is affordable.
2. Assess seizure frequency after 6–8 weeks. If < 50 % reduction, discuss options.
3. If seizures persist and you’re an adult, consider a switch to Xcopri with a carefully monitored titration plan.
4. Continue regular follow‑ups, monitor labs (for Xcopri) or mood (for Keppra), and adjust as needed.

Real‑World Stories

Case 1: Jake, 28, tried Keppra 1500 mg BID for eight months but still had 3‑4 focal seizures weekly. After a conversation with his neurologist, he switched to Xcopri 200 mg QD. Within three months, his seizures dropped to one per month, and after six months he was seizure‑free. He reports mild dizziness, but nothing that interferes with daily life.

Case 2: Maya, 10, was diagnosed with myoclonic seizures. Keppra (generic) at 20 mg/kg BID cleared her seizures within weeks. Xcopri wasn’t an option because she’s under 18, and the doctors preferred the proven pediatric data on Keppra.

Bottom Line

Both Xcopri and Keppra belong to the same family of focal seizure medication, yet they serve different roles. Xcopri may give you a stronger chance at seizure‑free days, especially if you’ve exhausted other treatments, but it comes with a higher cost, a need for careful titration, and a controlled‑substance label. Keppra offers flexibility, lower price, and a broader age range, making it the go‑to first‑line option for many patients.

Ultimately, the “best” choice hinges on your personal health story, how your body reacts, and practical factors like insurance coverage. If you’re unsure, grab a notebook, write down your current seizure frequency, any side‑effects you’ve noticed, and bring those notes to your next appointment. A candid conversation with your neurologist will help you weigh Xcopri side effects against the benefits of Keppra dosage flexibility and decide the path that feels safest and most effective for you.

What’s your experience with these meds? Have you tried one, the other, or both? Share your thoughts in the comments – your story could help someone else navigating the same decision. And remember, you’re never alone on this journey; a supportive doctor, a knowledgeable pharmacist, and a community that cares can make the difference.